NEJM· @NEJM · X·· 3 天前AI 评分22
AI 导读
对于急性冠脉综合征患者,普拉格雷与替格瑞洛孰应作为首选 P2Y12 抑制剂尚不明确。一段新的 Quick Take 视频总结了 SWITCH-SWEDEHEART 试验的研究结果。https://nej.md/4ks60ld
正文
Whether prasugrel or ticagrelor should be the preferred P2Y12 inhibitor for patients with an acute coronary syndrome is uncertain. Research findings from the SWITCH-SWEDEHEART trial are summarized in a new Quick Take video. https://nej.md/4ks60ld
来源:NEJM · x.com